Prognostic impact of S100A9 overexpression in non-small cell lung cancer

Abstract

S100 proteins have been implicated in the progression and metastasis of several cancers. Among the S100 family, S100A9 is reportedly expressed in non-small cell lung cancer (NSCLC), though the clinical significance and prognostic value of S100A9 expression in NSCLC remains unclear. The aim of the present study was to examine the relationship between S100A9 expression and prognosis in NSCLC patients. S100A9 expression was evaluated by immunohistochemical staining. Seventy patients with NSCLC who had undergone lung resection were enrolled in the study. Overexpression of S100A9 was observed in 38 (54.3%) patients. Kaplan-Meier analysis showed that, following surgery, patients overexpressing S100A9 had a significantly lower 5-year overall survival rate than patients with weak or no expression of S100A9 (P=0.005). This finding was also observed in pathological stage IA patients (P=0.03). Multivariate Cox regression analysis revealed overexpression of S100A9 to be an independent factor predictive of poor disease outcome (hazard ratio, 0.3; 95% confidence interval, 0.1-0.8; P=0.02). Our results suggest that overexpression of S100A9 is associated with a poor prognosis among NSCLC patients and could serve as a marker identifying patients who are at high risk, even at an early pathological stage.

Inhibition of the autocrine IL-6–JAK2–STAT3–calprotectin axis as targeted therapy for HR−/HER2+breast cancers

“…S100A8 and S100A9 are calcium-binding proteins that heterodimerize, forming a complex called calprotectin that is secreted (Gebhardt et al 2006;Ehrchen et al 2009). While the role of S100A8/9 as proinflammatory mediators secreted by immune cells is well documented, S100A8/9 proteins are also found up-regulated in multiple solid tumors and associated with poor prognosis characteristics (Arai et al 2008;Kawai et al 2011;Grebhardt et al 2014). Indeed, autocrine and paracrine exposure to calprotectin activates key signaling pathways involved in tumorigenesis (Gebhardt et al 2006;Hermani et al 2006;Ichikawa et al 2011;Acharyya et al 2012).…”

“…they have been mainly studied in the context of the immune system, S100A8/9 have been found to be up-regulated in multiple solid tumors and associated with poor prognosis (Arai et al 2008;Kawai et al 2011;Grebhardt et al 2014). Next, we analyzed the METABRIC data to investigate whether overexpression of S100A8/9 was observed in ER − /HER2 + primary breast tumors.…”

Proteomics biomarkers for non-small cell lung cancer

“…This suggests that these proteins play an important role in tumor immunology and cancer progression. Overexpression of this molecule has also a prognostic impact on NSCLC [46].…”

Support vector machines coupled with proteomics approaches for detecting biomarkers predicting chemotherapy resistance in small cell lung cancer

“…The protein peak m/z 10468 Da was identified as protein S100-A9, and further confirmed by western blot analysis, S100 protein family consists of at least 24 members, and are small Ca21 binding proteins that participate in many cellular functions including tumor growth (23). Protein S100-A9 (S100A9), was suggested to be a marker for pancreatic cancer, inflammatory bowel disease, lung adenocarcinoma and breast cancer (24).…”